What is the SYMPHONY Study?
The SYMPHONY Study is a clinical research trial currently being conducted at select centers in the US and Canada. The study is for people with narcolepsy who are experiencing excessive daytime sleepiness (EDS) and cataplexy (sudden muscle weakness). The SYMPHONY Study is evaluating AXS-12 (reboxetine) as an investigational oral medication to improve wakefulness and reduce occurrence of cataplexy.
What is Excessive Daytime Sleepiness (EDS)?
Excessive daytime sleepiness (EDS) is a persistent feeling of sleepiness commonly found in people with narcolepsy. EDS can affect normal sleep-wake cycles, causing people to fall asleep at unexpected times throughout the day.
What is Cataplexy?
Cataplexy is a sudden loss of muscle tone or weakness brought on by strong emotions like laughter, embarrassment, frustration or surprise. Sometimes there may be mild weakness, such as a drooping of the eyelids. Sometimes the attack could be severe and cause a total body collapse. Cataplexy occurs in 60-70% of people with narcolepsy. While most attacks are brief, some can last several minutes. Cataplexy is treatable and there are currently approved treatment options, but additional therapies are needed.
Who can participate?
People who are aged 25 to 65 who have narcolepsy and are experiencing cataplexy. Other criteria also apply.
If you’re living with narcolepsy and cataplexy, the SYMPHONY Study may be right for you. AXS-12, or reboxetine, is being evaluated as an investigational oral medication to improve wakefulness and reduce occurrence of cataplexy in people living with narcolepsy. If you are qualified to participate:
See If You Qualify
To see if you might qualify for the SYMPHONY Study, and to connect with a local study center to learn more, please take the questionnaire below.